Compare Stocks: NTLA, BEAM, CRSP, and NTLA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BEAM Beam Therapeutics	$29.76	$30.11	$16.02 ▼ $38.26	$3.07B	2.23	1.71 million shs	2.46 million shs
CRSP CRISPR Therapeutics	$59.50	$53.05	$44.12 ▼ $78.48	$5.75B	1.74	1.57 million shs	2.45 million shs
NTLA Intellia Therapeutics	$12.84	$13.47	$7.95 ▼ $28.25	$1.80B	1.81	3.54 million shs	3.34 million shs
NTLA Intellia Therapeutics	$12.84	$13.47	$7.95 ▼ $28.25	$1.80B	1.81	3.54 million shs	3.34 million shs

7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries.

"Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BEAM Beam Therapeutics	0.00%	+11.25%	+18.57%	+3.91%	+78.85%
CRSP CRISPR Therapeutics	0.00%	+11.11%	+27.85%	+18.15%	+9.54%
NTLA Intellia Therapeutics	0.00%	+7.81%	+19.66%	+1.90%	+22.05%
NTLA Intellia Therapeutics	0.00%	+7.81%	+19.66%	+1.90%	+22.05%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BEAM Beam Therapeutics	$29.76	$30.11	$16.02 ▼ $38.26	$3.07B	2.23	1.71 million shs	2.46 million shs
CRSP CRISPR Therapeutics	$59.50	$53.05	$44.12 ▼ $78.48	$5.75B	1.74	1.57 million shs	2.45 million shs
NTLA Intellia Therapeutics	$12.84	$13.47	$7.95 ▼ $28.25	$1.80B	1.81	3.54 million shs	3.34 million shs
NTLA Intellia Therapeutics	$12.84	$13.47	$7.95 ▼ $28.25	$1.80B	1.81	3.54 million shs	3.34 million shs

7 Stocks to Buy Before the Robotics Revolution

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BEAM Beam Therapeutics	0.00%	+11.25%	+18.57%	+3.91%	+78.85%
CRSP CRISPR Therapeutics	0.00%	+11.11%	+27.85%	+18.15%	+9.54%
NTLA Intellia Therapeutics	0.00%	+7.81%	+19.66%	+1.90%	+22.05%
NTLA Intellia Therapeutics	0.00%	+7.81%	+19.66%	+1.90%	+22.05%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BEAM Beam Therapeutics	2.69	Moderate Buy	$49.00	64.65% Upside
CRSP CRISPR Therapeutics	2.58	Moderate Buy	$68.06	14.38% Upside
NTLA Intellia Therapeutics	2.35	Hold	$21.15	64.74% Upside
NTLA Intellia Therapeutics	2.35	Hold	$21.15	64.74% Upside

Current Analyst Ratings Breakdown

Latest NTLA, BEAM, CRSP, and NTLA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/10/2026	BEAM Beam Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/7/2026	NTLA Intellia Therapeutics	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Outperform	$24.00
8/7/2026	NTLA Intellia Therapeutics	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Outperform	$24.00
8/6/2026	CRSP CRISPR Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral	$55.00
8/4/2026	CRSP CRISPR Therapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$82.00 ➝ $88.00
7/22/2026	CRSP CRISPR Therapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
7/17/2026	BEAM Beam Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	CRSP CRISPR Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	NTLA Intellia Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	NTLA Intellia Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/15/2026	NTLA Intellia Therapeutics	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Peer Perform ➝ Underperform	$9.00

(Data available from 8/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BEAM Beam Therapeutics	$139.74M	22.00	N/A	N/A	$12.20 per share	2.44
CRSP CRISPR Therapeutics	$3.51M	1,639.05	N/A	N/A	$20.17 per share	2.95
NTLA Intellia Therapeutics	$59.51M	30.24	N/A	N/A	$5.80 per share	2.21
NTLA Intellia Therapeutics	$59.51M	30.24	N/A	N/A	$5.80 per share	2.21

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BEAM Beam Therapeutics	-$79.99M	-$0.86	N/A	N/A	N/A	-54.75%	-30.71%	-24.07%	11/3/2026 (Estimated)
CRSP CRISPR Therapeutics	-$581.60M	-$4.76	N/A	N/A	N/A	-3,368.72%	-24.39%	-18.25%	11/9/2026 (Estimated)
NTLA Intellia Therapeutics	-$412.69M	-$3.36	N/A	N/A	N/A	-672.16%	-57.79%	-47.29%	11/5/2026 (Estimated)
NTLA Intellia Therapeutics	-$412.69M	-$3.36	N/A	N/A	N/A	-672.16%	-57.79%	-47.29%	11/5/2026 (Estimated)

Latest NTLA, BEAM, CRSP, and NTLA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	NTLA Intellia Therapeutics	-$0.7993	-$0.80	-$0.0007	-$0.80	$12.98 million	$7.66 million
8/6/2026	Q2 2026	NTLA Intellia Therapeutics	-$0.7993	-$0.80	-$0.0007	-$0.80	$12.98 million	$7.66 million
8/4/2026	Q2 2026	BEAM Beam Therapeutics	-$1.11	-$1.18	-$0.07	-$1.18	$16.37 million	$0.49 million
8/3/2026	Q2 2026	CRSP CRISPR Therapeutics	-$1.19	-$0.94	+$0.25	-$0.94	$7.45 million	$10.18 million
6/30/2026	Q2 2026	CRSP CRISPR Therapeutics	N/A	-$0.94	N/A	-$0.94	N/A	$10.18 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BEAM Beam Therapeutics	N/A	N/A	N/A	N/A	N/A
CRSP CRISPR Therapeutics	N/A	N/A	N/A	N/A	N/A
NTLA Intellia Therapeutics	N/A	N/A	N/A	N/A	N/A
NTLA Intellia Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BEAM Beam Therapeutics	0.09	14.57	14.57
CRSP CRISPR Therapeutics	0.34	17.85	17.85
NTLA Intellia Therapeutics	N/A	6.65	6.65
NTLA Intellia Therapeutics	N/A	6.65	6.65

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BEAM Beam Therapeutics	99.68%
CRSP CRISPR Therapeutics	69.20%
NTLA Intellia Therapeutics	88.77%
NTLA Intellia Therapeutics	88.77%

Insider Ownership

Company	Insider Ownership
BEAM Beam Therapeutics	3.80%
CRSP CRISPR Therapeutics	5.20%
NTLA Intellia Therapeutics	3.50%
NTLA Intellia Therapeutics	3.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BEAM Beam Therapeutics	510	103.29 million	99.36 million	Optionable
CRSP CRISPR Therapeutics	460	96.69 million	91.67 million	Optionable
NTLA Intellia Therapeutics	600	140.13 million	135.22 million	Optionable
NTLA Intellia Therapeutics	600	140.13 million	135.22 million	Optionable

NTLA, BEAM, CRSP, and NTLA Headlines

Recent News About These Companies

Orchard Capital Management LLC Invests $1.34 Million in Intellia Therapeutics, Inc. $NTLA

August 23 at 6:00 AM | marketbeat.com

Elevation Point Wealth Partners LLC Acquires New Position in Intellia Therapeutics, Inc. $NTLA

August 23 at 4:23 AM | marketbeat.com

Intellia Therapeutics (NASDAQ:NTLA) Shares Down 6.4% - Time to Sell?

August 20, 2026 | marketbeat.com

Bank of America Corp DE Grows Stock Position in Intellia Therapeutics, Inc. $NTLA

August 20, 2026 | marketbeat.com

Intellia Therapeutics (NASDAQ:NTLA) Stock Price Up 10.7% - Here's What Happened

August 19, 2026 | marketbeat.com

Intellia (NTLA) Q2 2026 Earnings Call Transcript

August 13, 2026 | finance.yahoo.com

Wasatch Advisors LP Sells 134,215 Shares of Intellia Therapeutics, Inc. $NTLA

August 13, 2026 | marketbeat.com

HC Wainwright Has Negative Outlook of NTLA FY2026 Earnings

August 13, 2026 | americanbankingnews.com

Intellia Therapeutics, Inc. $NTLA Shares Acquired by Royal Bank of Canada

August 12, 2026 | marketbeat.com

Morgan Stanley Sticks to Their Hold Rating for Intellia Therapeutics (NTLA)

August 12, 2026 | theglobeandmail.com

Research Analysts Offer Predictions for NTLA FY2026 Earnings

August 11, 2026 | marketbeat.com

Equities Analysts Issue Forecasts for NTLA Q2 Earnings

August 10, 2026 | marketbeat.com

Intellia Therapeutics (NASDAQ:NTLA) Issues Earnings Results

August 8, 2026 | marketbeat.com

Bank of America Securities Remains a Hold on Intellia Therapeutics (NTLA)

August 8, 2026 | theglobeandmail.com

Intellia upgraded at Evercore ISI on nex-z hypothesis

August 8, 2026 | seekingalpha.com

Will Intellia’s (NTLA) Narrowing Losses and Heavy R&D Spend Shift Its Risk Reward Narrative?

August 8, 2026 | finance.yahoo.com

Intellia Therapeutics (NASDAQ:NTLA) Stock Rating Lowered by Wall Street Zen

August 8, 2026 | marketbeat.com

NTLA Q2 Earnings In Line, Top Line Misses on Lower Regeneron Revenues

August 7, 2026 | zacks.com

Intellia Therapeutics Q2 Earnings Call Highlights

August 7, 2026 | marketbeat.com

Intellia Therapeutics, Inc. (NTLA) Q2 2026 Earnings Call Transcript

August 6, 2026 | seekingalpha.com

Intellia Therapeutics (NTLA) Q2 2026

August 6, 2026 | 247wallst.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

NTLA, BEAM, CRSP, and NTLA Company Descriptions

Beam Therapeutics NASDAQ:BEAM

$29.76 0.00 (0.00%)

As of 08/21/2026 04:00 PM Eastern

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

CRISPR Therapeutics NASDAQ:CRSP

$59.50 0.00 (0.00%)

As of 08/21/2026 04:00 PM Eastern

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

Intellia Therapeutics NASDAQ:NTLA

$12.84 0.00 (0.00%)

As of 08/21/2026 04:00 PM Eastern

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Intellia Therapeutics NASDAQ:NTLA

$12.84 0.00 (0.00%)

As of 08/21/2026 04:00 PM Eastern

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NTLA, BEAM, CRSP, and NTLA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NTLA, BEAM, CRSP, and NTLA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NTLA, BEAM, CRSP, and NTLA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

NTLA, BEAM, CRSP, and NTLA Company Descriptions

Beam Therapeutics NASDAQ:BEAM

CRISPR Therapeutics NASDAQ:CRSP

Intellia Therapeutics NASDAQ:NTLA

Intellia Therapeutics NASDAQ:NTLA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NTLA, BEAM, CRSP, and NTLA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NTLA, BEAM, CRSP, and NTLA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NTLA, BEAM, CRSP, and NTLA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

NTLA, BEAM, CRSP, and NTLA Company Descriptions

Beam Therapeutics NASDAQ:BEAM

CRISPR Therapeutics NASDAQ:CRSP

Intellia Therapeutics NASDAQ:NTLA

Intellia Therapeutics NASDAQ:NTLA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools